Torii Pharmaceutical Co Ltd
TSE:4551
Torii Pharmaceutical Co Ltd
Interest Income Expense
Torii Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Interest Income Expense
¥115m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
14%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Interest Income Expense
-¥172.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-28%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Interest Income Expense
¥47B
|
CAGR 3-Years
172%
|
CAGR 5-Years
53%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Interest Income Expense
¥45.9B
|
CAGR 3-Years
33%
|
CAGR 5-Years
25%
|
CAGR 10-Years
13%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Interest Income Expense
¥1B
|
CAGR 3-Years
164%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Interest Income Expense
-¥10.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
115m
JPY
Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Interest Income Expense amounts to 115m JPY.
What is Torii Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
14%
Over the last year, the Interest Income Expense growth was -80%. The average annual Interest Income Expense growth rates for Torii Pharmaceutical Co Ltd have been -2% over the past three years , -12% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet